Incyte Corp Files Proxy Statement
Ticker: INCY · Form: DEFA14A · Filed: May 30, 2024 · CIK: 879169
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
Related Tickers: INCY
TL;DR
Incyte proxy statement out - shareholders vote on directors & exec pay soon.
AI Summary
Incyte Corporation filed a Definitive Proxy Statement (DEFA14A) on May 30, 2024, detailing matters to be voted on by shareholders. The filing outlines the company's governance, executive compensation, and other corporate actions requiring shareholder approval. Key proposals likely include the election of directors and ratification of auditors.
Why It Matters
This filing provides shareholders with crucial information to make informed voting decisions on company leadership and policies, impacting the future direction and governance of Incyte Corporation.
Risk Assessment
Risk Level: low — This is a standard proxy filing, providing information to shareholders for voting purposes, and does not inherently represent a new risk to the company.
Key Players & Entities
- Incyte Corporation (company) — Registrant
- 0001104659-24-066604.txt (document) — Filing document identifier
- 20240530 (date) — Filing date
- DEFA14A (document) — Form type
FAQ
What is the purpose of a DEFA14A filing?
A DEFA14A filing, or Definitive Proxy Statement, is used by companies to solicit votes from shareholders on various corporate matters, such as the election of directors, executive compensation, and other proposals.
When was this specific DEFA14A filing made by Incyte Corporation?
Incyte Corporation filed this DEFA14A on May 30, 2024.
What is the Central Index Key (CIK) for Incyte Corporation?
The Central Index Key (CIK) for Incyte Corporation is 0000879169.
What is the Standard Industrial Classification (SIC) code for Incyte Corporation?
The Standard Industrial Classification (SIC) code for Incyte Corporation is 8731, which falls under Services-Commercial Physical & Biological Research.
Where is Incyte Corporation's principal executive office located?
Incyte Corporation's principal executive office is located at 1801 Augustine Cut-Off, Wilmington, DE 19803.
Filing Stats: 409 words · 2 min read · ~1 pages · Grade level 14.5 · Accepted 2024-05-30 15:12:24
Filing Documents
- tm2415982d1_defa14a.htm (DEFA14A) — 13KB
- tm2415982d1_defa14aimg001.jpg (GRAPHIC) — 13KB
- 0001104659-24-066604.txt ( ) — 33KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12 INCYTE CORPORATION (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Incyte Corporation 1801 Augustine Cut-Off Wilmington, Delaware 19803 Supplement to Proxy Statement for Annual Meeting of Stockholders Wednesday, June 12, 2024 9:00 AM Eastern Daylight Time 1815 Augustine Cut-Off, Wilmington, Delaware 19803 This supplement, dated May 30, 2024, supplements the definitive proxy statement (the “Proxy Statement”) of Incyte Corporation (the “Company” or “Incyte”) filed with the Securities and Exchange Commission on April 29, 2024, relating to the Company’s Annual Meeting of Stockholders to be held on June 12, 2024 (the “2024 Annual Meeting”). Incyte is providing the following supplemental information regarding its executive compensation program as discussed in the section under the heading “Executive Compensation – Compensation Discussion and Analysis” of the Proxy Statement. Make-Whole Equity Award to Dr. Cagnoni As disclosed in the Proxy Statement, in connection with Dr. Pablo J. Cagnoni joining Incyte as President, Research and Development, Dr. Cagnoni received an initial grant of RSUs on June 5, 2023 to acquire 192,400 shares, which vest in four equal annual installments commencing June 1, 2026, recognized that Dr. Cagnoni would be forfeiting certain equity compensation from his previous employer in order to join Incyte. Accordingly, this initial RSU grant made to Dr. Cagnoni was designed as a make-whole award to offset the estimated value of such forfeited compensation. In addition, as described in the Proxy Statement, the time-based vesting of this award serves a critical retention function. In light of the rationale described in the Proxy Statement, and the additional information set forth in this supplement, Incyte’s Board reiterates its original recommendation to vote FOR Item 2 – the Advisory Vote to Approve Executive Compensation.